Announced details
Chronic liver disease
The paper suggests therapeutic effects including reduced liver injury and improved liver fibrosis. However, no figures were disclosed.
The announcement concerns Redasemtide, our development product. The clinical trial is described as investigator-initiated, but the relationship with the investigators and medical institutions is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Paper published in Inflammation and Regeneration, “Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial,” DOI: https://doi.org/10.1186/s41232-026-00421-9
| Item | Details |
|---|---|
| Names of Products / Services Covered | Redasemtide (HMGB1 peptide, S-005151) |
| Relationship with the Company | The announcement concerns Redasemtide, our development product. The clinical trial is described as investigator-initiated, but the relationship with the investigators and medical institutions is Not disclosed. |
| Applicable area | Chronic liver disease |
| Quantitative Effects | The paper suggests therapeutic effects including reduced liver injury and improved liver fibrosis. However, no figures were disclosed. |
| Source | Paper published in Inflammation and Regeneration, “Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial,” DOI: https://doi.org/10.1186/s41232-026-00421-9 |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A paper on a previously conducted phase 2 investigator-initiated clinical trial for chronic liver disease was published.